Treatment options for prostate cancer consist of radical prostatectomy, hormonal therapy and radiation therapy.
Hormonal and radiation therapy have well-known, often profound, effects on the histological appearance of benign and malignant prostate tissue. Novel therapies including focal ablative treatments, chemotherapies and targeted molecular therapies are beginning to emerge and pathologists will play a central role in documenting the effects of these treatments at the tissue level. As such, knowledge of treatment-related changes and access to clinical information are essential to ensure accurate interpretation and reporting of post-treatment prostate specimens by pathologists.
Written by:
Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L, Di Primio R, Montironi R. Are you the author?
Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy.
Reference: Int J Immunopathol Pharmacol. 2013 Apr-Jun;26(2):291-8.
PubMed Abstract
PMID: 23755744
UroToday.com Prostate Cancer Section
